A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2018
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- Acronyms Her+XELOX
- 28 Jun 2018 Planned End Date changed from 1 Mar 2018 to 1 Nov 2018.
- 28 Jun 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2018.
- 13 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History